Home
overview

"This programme provides a forum for interdisciplinary exchange on the current state-of-the-art of nanotechnology-enabled drug delivery systems research and development as well as on legal and regulatory challenges facing particulate nanomedicines..." to read on Click here (Conference Chair Day 1 - Dr SM Moghimi, Senior Lecturer (Biopharmacy and Molecular Targeting), Molecular Targeting and Polymer Toxicology Group, School of Pharmacy and Biomolecular Sciences, University of Brighton)

Announcing the SMi Group's 4th Annual Drug Delivery Global Summit; Optimising Drug Delivery Using Nanotechnology; bringing together the key industry leaders to discuss the current and future technological developments and formulation trends.

This is a must-attend event for all those involved in addressing the growing challenges in the drug delivery field. This two day intensive forum will help you learn more about:

  • The drug delivery business: Examine the adjusting business strategies and the global trends in deal making in the drug delivery
  • The role of nanotechnology in the drug delivery: Discover the impact of nanotechnology on drug delivery and the view of regulatory bodies on nanotechnology and nonomedicine
  • Advancing drug delivery technology: review the emerging delivery systems technology and address the challenges faced by the industry

The conference features an excellent opportunity to hear from an international panel of experts, including:
  • Dr Luk Chiu Li, Director, Global Drug Delivery, Life Cycle Technology, Abbott Laboratories
  • Dr SM Moghimi, Senior Lecturer (Biopharmacy and Molecular Targeting), Molecular Targeting and Polymer Toxicology Group, School of Pharmacy and Biomolecular Sciences, University of Brighton
  • Peter Villax, Vice President, Pharma, Hovione
  • Dr David Cipolla, Senior. Director of Pharmaceutical Sciences, Aradigm Corporation
  • Dr Tomas Landh, Principal Scientist, Diabetes Research Unit, Preformulation and Delivery, Novo Nordisk
  • Bruce M Pratt, Vice President, Science Development, Genzyme
  • James Eshelby, Associate Director, Strategic Alliances, Pfizer
  • Dr James D Talton, President & Chief Scientific Officer, Nanotherapeutics

‘The US advanced drug delivery market will grow more than 18 per cent and exceed $76 bn (€62 bn) by 2014, spurred on by new technologies emerging from the biotech and biopharmaceutical pipelines’  - Nanomarkets - industry consulting firm

Who should attend The Drug Delivery Global Summit?
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within:

  • Drug Delivery
  • Drug Delivery Systems
  • Business Development
  • Licensing Strategy
  • Strategic Planning & Development
  • Technology Development
  • Marketing
  • Research & Development

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr SM Moghimi

Dr SM Moghimi, Senior Lecturer (Biopharmacy & Molecular Targeting), Molecular Targeting & Polymer Toxicology Group, School of Pharmacy & Biomolecular Sciences, University of Brighton

9:10 SUCCESSFUL PARTNERING IN THE DRUG DELIVERY MARKET PLACE

Dr James Eshelby

Dr James Eshelby, Director, Strategic Alliances , Pfizer

  • Factors driving this change
  • What are the likely opportunities and challenges?
  • How do you maximise the chances of successful partnering?
  • 9:50 DRUG DELIVERY DEAL MAKING TRENDS

    Dr Bruce Pratt

    Dr Bruce Pratt, Vice President, Science Development, Genzyme

  • Finding the ideal partner
  • Building successful partnerships
  • Deal structure considerations
  • IP and Relationship management
  • 10:30 Morning Coffee

    11:30 BRIDGING API MANUFACTURING AND FORMULATION THROUGH PARTICLE DESIGN

    Dr Filipe Gaspar

    Dr Filipe Gaspar, Particle Design Discipline Director, R&D Business Unit, Hovione

  • Overcoming bioavailability problems
  • Particle engineering technologies for better drug performance
  • Spray drying: from nanosize powders to direct compressibles
  • 12:10 Networking Lunch

    13:30 ORAL BIOAVAILABILITY ENHANCEMENT OF POORLY SOLUBLES

    Dr Rainer Muller

    Dr Rainer Muller, Department of Pharmacy, Freie Universitat Berlin

  • SmartCrystal technology: production, special features
  • Dermal products with SmartCrystals
  • Oral bioavailability enhancement by lipid nanoparticles
  • Nanosized lipids: Solid Lipid Nanoparticles (SLN) vs. Nanostructured
  • Lipid Carriers (NLC)
  • Large scale production processes
  • In vivo study results
  • 14:10 THE IMPACT OF NANOTECHNOLOGY ON DRUG DELIVERY

    Dr James D Talton

    Dr James D Talton, President & Chief Scientific Officer, Nanotherapeutics

  • Examining the potential for nanotechnology
  • Implementing nanotechnology into drug delivery processes
  • New applications in drug delivery enabled by nanotechnology developments
  • 14:50 DRUG NANOCRYSTAL TECHNOLOGY FOR DELIVERY OF POORLY SOLUBLES

    Dr Rainer Muller

    Dr Rainer Muller, Department of Pharmacy, Freie Universitat Berlin

  • Pearl milling vs high pressure homogenisation technologies
  • Amorphous drug nanoparticles
  • Approaches to formulate oral drug nanocrystals
  • Products on the market (pharmaceuticals and cosmetics)
  • Upcoming trends in drug nanocrystal technology (e.g. targeted nanocrystals, Nanopure CT)
  • 15:30 Afternoon Tea

    15:50 CHALLENGES OF TOXICITY WITH NANOMEDICINE

    Dr SM Moghimi

    Dr SM Moghimi, Senior Lecturer (Biopharmacy & Molecular Targeting), Molecular Targeting & Polymer Toxicology Group, School of Pharmacy & Biomolecular Sciences, University of Brighton

  • Non-IgE-mediated hypersensitivity reactions and symptoms
  • Hypersensitivity reactions to micelles, liposomes and supramolecular systems
  • Underlying principles and mechanisms
  • Strategies and possible solutions
  • 16:30 THE REGULATORY PERSPECTIVE OF NANOTECHNOLOGY & NANOMEDICINE

    Dr Evdokia Korakianiti

    Dr Evdokia Korakianiti, Scientific Administrator, Human Unit, EMEA

  • Key aspects of the European regulatory environment in relation to nanomedicine
  • Current EMEA thinking and future expectations
  • Regulatory challenges
  • EMEA initiatives to support emerging therapies and technologies
  • EMEA contribution to EC activities and internal collaboration in the field of nanomedicine
  • 17:10 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Tomas Landh

    Dr Tomas Landh, Principal Scientist, Diabetes Research Unit, Preformulation & Delivery, Novo Nordisk

    9:10 PROTEIN DRUG DELIVERY

    Dr Tomas Landh

    Dr Tomas Landh, Principal Scientist, Diabetes Research Unit, Preformulation & Delivery, Novo Nordisk

  • Protein and peptide therapeutics – selecting non-invasive route(s) of administration
  • Protein drug delivery technologies – mapped with respect to route(s) of administration
  • Optimizing the protein/peptide - technology fit – scout – screen – select
  • Challenges in the process
  • Future trends to consider for non-invasive protein drug delivery
  • 9:50 DRUG DELIVERY OF MONOCLONAL ANTIBODIES

    Dr Luk Chiu Li

    Dr Luk Chiu Li, Director, Global Drug Delivery, Life Cycle Technology, Abbott Laboratories

  • Characteristics of monoclonal antibody therapies and products
  • Approaches for developing high concentration formulations
  • Injectable device delivery
  • Non-parenteral delivery
  • 10:30 Morning Coffee

    10:50 POLYSIALYLATION

    Dr Sanjay Jain

    Dr Sanjay Jain, Principal Scientist, Lipoxen

  • The challenges of protein delivery
  • Existing delivery solutions
  • Pros and cons of present delivery systems
  • Polysialylation: Solution for the ‘next generation’ of drugs and drug delivery systems
  • Future prospects
  • 11:30 INHALED INSULIN: SUCCESS STORIES & NEXT STEPS

    Dr Brad Benson

    Dr Brad Benson, Vice President, Pharmaceutical Technology Development, Nektar Therapeutics

    Andrew Clark

    Andrew Clark, Chief Technical Officer, Nektar Therapeutics

    12:10 Networking Lunch

    13:30 NEW LIPOSOMAL APPROACHES IN MODERN BIOTECHNOLOGY

    Dr Andreas Wagner

    Dr Andreas Wagner, Head, Liposome Technology, Polymun Scientific

  • Liposomes as drug delivery systems and vaccine carrier
  • Novel liposome technology platform – technology presentation
  • Advantages and improvements
  • Liposome examples – a detailed look into oligonucleotide, peptide and protein carrying liposomes
  • Preclinical and clinical data
  • 14:10 INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES

    Dr Rick Constantino

    Dr Rick Constantino, Senior Director, Drug Development, Nastech Pharmaceutical

  • Macromolecular drugs are challenging to deliver due to their relative fragility, wide range of physiochemical properties, low bioavailability when taken orally, and potential issues with injections
  • Intranasal (IN) delivery provide potential advantages such as rapid onset of Cmax, no 1st-pass metabolism, reduced side effects and toxicity, increased patient comfort and compliance, IP/life cycle management, applicability to a wide range of therapeutics and avoidance of needle sticks in health care settings
  • Nastech is employing a high-throughput tissue-based screening process for screening of IN formulations that provide opening of nasal mucosal tight junctions with exhibiting low cytotoxicity and maintaining high cell viability
  • Nastech is pursuing clinical development of a variety of therapeutic peptides for IN delivery, e.g., insulin
  • 14:50 NASAL DRUG DELIVERY OF PROTEINS

    Dr Anette  Sams

    Dr Anette Sams, Research Scientist, ADME and Assay Technology, Novo Nordisk

  • Brief overview on current pipeline technologies for nasal peptide delivery
  • Brief historic review on nasal insulin
  • Characterization/comparison on various in vitro models
  • Enhancer characterisation
  • 15:30 Afternoon Tea

    15:50 THE CHALLENGES OF INHALED DRUG DELIVERY

    Peter Villax

    Peter Villax, Vice President, Pharma, Hovione S A

  • How efficiency and simplicity can co-exist
  • Changing the behaviour of particles
  • Understanding a complex development cycle: from API to clinical effect
  • 16:30 NOVEL CONCEPTS FOR PULMONARY DRUG DELIVERY

    Dr David Cipolla

    Dr David Cipolla, Senior Director, Pharmaceutical Sciences , Aradigm Corporation

  • Suitable formulations
  • Aerosol inhalation and intratracheal instillation
  • Distribution of small and large molecules
  • Drug absorption
  • 17:10 Chairman’s Closing Remarks and Close of Conference

    +

    Dexter House

    Royal Mint Court
    Tower Gateway
    London EC3N 4QN
    United Kingdom

    Dexter House

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.